Sandoz to strengthen Danish market position and Nordic operations with acquisition of danish Astra Zeneca's generics subsidiary

Strategic acquisition of Durascan makes Sandoz number two player in local generics market and provides operational hub for entire Nordic region

01-Jul-2004

Sandoz announced the acquisition of Durascan, the generic subsidiary of Astra Zeneca in Denmark, in a transaction aimed at claiming the number two position in the Danish generics market and establishing a new operational hub in the Nordic region. Financial details of the transaction were not disclosed.

With net sales of EUR25 million in 2003, Durascan has a broad portfolio of generic medicines that provide growth opportunities for Sandoz throughout the Nordic region. In addition, Durascan provides Sandoz with state-of-the-art quality assurance and logistics facilities, making it an attractive operational platform to fuel regional growth.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances